Industry Explorers Blaze On

Industry Explorers Blaze On is a series of interviews with senior executives who played a historical role in drug discovery and development and are still active in the biopharma industry.

  • Industry Explorers Blaze On: Leading Business With Science — Part 2
    Industry Explorers Blaze On: Leading Business With Science — Part 2

    We continue the story of Geert Cauwenbergh whose nearly 40 years in the industry included work with Paul Janssen as well as being a startup entrepreneur with RXi Pharmaceuticals.

  • Leading Business With Science: Geert Cauwenbergh of RXi
    Leading Business With Science: Geert Cauwenbergh of RXi

    Geert Cauwenbergh now can look back at his almost four decades in the industry — from his formative years working with Paul Janssen building a small company into a global phenomenon, to his later years as a startup entrepreneur with RXi — and reflect on how most of it has turned upon a snap decision.

  • Abbey Meyers: Did The Pioneer Of Orphan Drugs Spark Biopharma?
    Abbey Meyers: Did The Pioneer Of Orphan Drugs Spark Biopharma?

    By the time Abbey Meyers, founder of the National Organization for Rare Disorders (NORD) and chief architect of the ODA, wrote her letter to me a few years later, the paradoxical conflict of orphan-drug availability versus price had become obvious.

  • David Hale: How The Journey To Entrepreneurial Biotech Begins
    David Hale: How The Journey To Entrepreneurial Biotech Begins

    These are the stories of longtime leaders, still active in the industry, sharing their historical perspectives on innovation in the life sciences industry. This month: Why David Hale is considered an icon of entrepreneurial biotech.

  • Industry Explorers Blaze On: R&D Veteran William Comer Of NeuroGenetic
    Industry Explorers Blaze On: R&D Veteran William Comer Of NeuroGenetic

    The chairman of Bristol-Myers summoned the head of R&D into his office. “Bill, go down and check out the ruckus on the street,” he said. “Something about our new AIDS drug.” When Dr. William Comer exited the front door of the company’s New York City headquarters, he saw a small group of men marching around on the sidewalk, holding signs, blowing trumpets, beating drums, and chanting loudly.

More From Industry Explorers Blaze On

BEYOND THE PRINTED PAGE

  • Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma

    Daniel Skovronsky, M.D., Ph.D., is the SVP of clinical and product development at Eli Lilly and Company. But prior to taking on this role, he held the title of CEO of Avid Radiopharmaceuticals — a company he founded in Philadelphia while still a graduate student at the University of Pennsylvania. This article explores some of the differences between this executives past and present roles, and is a good prequel to the upcoming article that explores how he went about building a $300 million company.

  • Does The Biopharmaceutical Industry Need To Broaden Its Horizons?

    When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”

  • What Might Be The Best Predictor Of Future Performance At Axovant Sciences?

    Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current  CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

  • Why <em>Every</em> Company Needs A Bio Strategy
    Why Every Company Needs A Bio Strategy

    Today we stand on the precipice overlooking a new frontier — the century of biology, and businesses of all kinds need to be prepared to not only embrace what is coming, but have a strategy for how to leverage biology for the betterment of their businesses and the good of the planet.

  • What Is BIO Hoping To See Among Session Submissions For 2018?
    What Is BIO Hoping To See Among Session Submissions For 2018?

    Life Science Leader Chief Editor Rob Wright is cochairing the 2018 BIO educational program planning committee. In this blog he talks about why this was the earliest the planning committee has ever met and what you can do to submit interesting and novel session proposals that will get the attention of the committee.

More From Life Science Leader Blogs

@LIFESCILEADER1